Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis

2012 ◽  
Vol 313 (1-2) ◽  
pp. 167-177 ◽  
Author(s):  
Violaine K. Harris ◽  
Qi Jiang Yan ◽  
Tamara Vyshkina ◽  
Sadia Sahabi ◽  
Xinhe Liu ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Experimental Model ◽  
Intrathecal Injection ◽  
Neural Progenitors

scholarly journals Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis

EBioMedicine ◽  
2018 ◽  
Vol 29 ◽  
pp. 23-30 ◽  
Author(s):  
Violaine K. Harris ◽  
James Stark ◽  
Tamara Vyshkina ◽  
Leslie Blackshear ◽  
Gloria Joo ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Phase I ◽  
Phase I Trial ◽  
Progressive Multiple Sclerosis ◽  
Neural Progenitors

Protective effects of intravitreal administration of mesenchymal stem cell-derived exosomes in an experimental model of optic nerve injury

2021 ◽  
Vol 407 (1) ◽  
pp. 112792
Author(s):  
Yi Cui ◽  
Chengyi Liu ◽  
Li Huang ◽  
Jing Chen ◽  
Nuo Xu
Keyword(s):  
Stem Cell ◽  
Optic Nerve ◽  
Mesenchymal Stem Cell ◽  
Experimental Model ◽  
Nerve Injury ◽  
Protective Effects ◽  
Optic Nerve Injury

scholarly journals Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis

2018 ◽  
Vol 4 (1) ◽  
pp. 205521731876528 ◽  
Author(s):  
Sarah M Planchon ◽  
Karen T Lingas ◽  
Jane Reese Koç ◽  
Brittney M Hooper ◽  
Basabi Maitra ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cells ◽  
Cell Culture ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Phase I ◽  
Mesenchymal Stem Cell Culture ◽  
Stem Cell Culture ◽  
Multiple Sclerosis Patients

Background Multiple sclerosis is an inflammatory, neurodegenerative disease of the central nervous system for which therapeutic mesenchymal stem cell transplantation is under study. Published experience of culture-expanding multiple sclerosis patients’ mesenchymal stem cells for clinical trials is limited. Objective To determine the feasibility of culture-expanding multiple sclerosis patients’ mesenchymal stem cells for clinical use. Methods In a phase I trial, autologous, bone marrow-derived mesenchymal stem cells were isolated from 25 trial participants with multiple sclerosis and eight matched controls, and culture-expanded to a target single dose of 1–2 × 106 cells/kg. Viability, cell product identity and sterility were assessed prior to infusion. Cytogenetic stability was assessed by single nucleotide polymorphism analysis of mesenchymal stem cells from 18 multiple sclerosis patients and five controls. Results One patient failed screening. Mesenchymal stem cell culture expansion was successful for 24 of 25 multiple sclerosis patients and six of eight controls. The target dose was achieved in 16–62 days, requiring two to three cell passages. Growth rate and culture success did not correlate with demographic or multiple sclerosis disease characteristics. Cytogenetic studies identified changes on one chromosome of one control (4.3%) after extended time in culture. Conclusion Culture expansion of mesenchymal stem cells from multiple sclerosis patients as donors is feasible. However, culture time should be minimized for cell products designated for therapeutic administration.

Autologous mesenchymal stem cell transplantation in patients with multiple sclerosis

2013 ◽  
Vol 333 ◽  
pp. e383
Author(s):  
Y. Motuzova ◽  
O. Ionova ◽  
M. Zafranskaya ◽  
A. Borisov ◽  
D. Nizheharodova ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Mesenchymal Stem Cell Transplantation
Sign in / Sign up

Export Citation Format

Share Document